Vanda Pharmaceuticals Secures FDA Approval for BYSANTI™ in Bipolar I and Schizophrenia
Summary
Vanda Pharmaceuticals announced FDA approval for BYSANTI™ (milsaperidone), a new chemical entity, for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for the treatment of schizophrenia in adults, with commercial launch expected in Q3 2026.
Key Events
-
FDA Approves BYSANTI™ (milsaperidone)
The U.S. Food and Drug Administration (FDA) has approved BYSANTI™ (milsaperidone) tablets, a new chemical entity (NCE), for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for the treatment of schizophrenia in adults.
-
Commercial Launch Expected Q3 2026
Vanda Pharmaceuticals anticipates commercial availability of BYSANTI™ in the third quarter of 2026.
-
Long-Term Market Exclusivity
BYSANTI™ marketing exclusivity is expected to be protected by regulatory data exclusivity and issued US patents, with the latest expiring in 2044, providing a robust foundation for long-term revenue.
-
Second New Drug Approval in Two Months
This marks the second new drug approval for Vanda in less than two months, following the approval of NEREUS™ in December 2025, indicating strong pipeline execution amidst recent financial and regulatory challenges.
Analysis
This FDA approval for BYSANTI™ (milsaperidone) is a critical positive development for Vanda Pharmaceuticals, especially following recent financial losses and the FDA's rejection of its sNDA for HETLIOZ. As a new chemical entity (NCE) approved for two significant psychiatric conditions, bipolar I disorder and schizophrenia, BYSANTI™ represents a substantial new revenue opportunity. The anticipated commercial launch in Q3 2026 and patent exclusivity extending to 2044 provide a long runway for growth and could significantly improve the company's financial outlook and investor sentiment, which has been challenged by recent setbacks.
At the time of this filing, VNDA was trading at $8.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $340.5M. The 52-week trading range was $3.81 to $9.60. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.